**Remdesivir process at St. Vincent’s Hospital, Portland, OR**

**Process for obtaining Remdesivir:**

(1)   **Clinical Trial**: we are a clinical trial site for 2 Gilead trials in moderate and severe pneumonia. Dr. Pusch is the primary investigator and we anticipate enrollment may start later this week.

a.       If you have a COVID patient and the physician would like to use remdesivir, please contact Dr. Pusch first to inquire about enrolling in our clinical trial. If he is not available, you can contact Drs. Marfori or Cameron.

b.      Right now, mechanically ventilated patients and pediatrics are excluded from the trial. That may change and I will try to keep you all informed. Dr. Pusch will evaluate the patient for additional inclusion/exclusion criteria.

c.       Note that patients may be excluded from the trial or require a washout period if they receive any other experimental therapy prior to enrollment(e.g. hydroxychloroquine, kaletra)

(2)   **Compassionate/Emergency Use**: For patients that do not qualify for the clinical trial, we can try to obtain remdesivir via compassionate use. This is a multi-step process that includes Gilead approval, FDA approval, and our local IRB approval. They should have an ID consult for this so that I can help with the process.

a.       Patients CAN receive experimental therapy (e.g. hydroxychloroquine, kaletra) and still qualify for compassionate use, it will just need to be discontinued once remdesivir is approved.

**Patients on Remdesivir:**

-          The pharmacy manual is on the COVID PSV sharepoint site that describes reconstitution and administration

-          MOA: adenosine analog, incorporated into viral RNA and causes premature termination

-          Dose is 200mg IV loading dose followed by 100 mg every 24 hours

o   Duration is 5-10 days depending on the clinical trial

o   Compassionate use is 10 days

-          Orders can be found in the data base under Â“STUDY-remdesivirÂ”. Make sure to select the non-placebo orders for compassionate use.

-          Potential adverse events will be monitored closely via the study or compassionate protocol. If you have any concerns, please reach out to Dr. Pusch.